HBV

Choose Selective HBV Inhibitors

HBV Products

  • All (8)
  • HBV Inhibitors (7)
  • HBV Modulators (1)
  • New HBV Products
Catalog No. Product Name Information Product Use Citations Product Validations
S0038 AB-423 AB-423, a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors, shows potent inhibition of HBV replication with EC50 of 0.08 μM - 0.27 μM and EC90 of 0.33 μM - 1.32 μM in cells. Phase 1.
S0285 Bay 41-4109 racemate BAY 41-4109 racemate (BAY41-4109 Racemic) is a mixture of R-isomer of BAY 41-4109 and S-isomer of BAY 41-4109. BAY 41-4109 an antiviral compound that inhibits human hepatitis B virus (HBV) with IC50 of 53 nM.
Nat Commun, 2021, 12(1):2114
S1208 Doxorubicin (Adriamycin) HCl Doxorubicin (Adriamycin, NSC 123127, DOX, Hydroxydaunorubicin) HCl is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage, mitophagy and apoptosis in tumor cells. Doxorubicin reduces basal phosphorylation of AMPK. Doxorubicin is used in the concomitant treatment of HIV-infected patients but is found to be at high risk of HBV reactivation.
Oncol Rep, 2022, 47(1)18
Nat Genet, 2021, 10.1038/s41588-021-00893-0
Cancer Cell, 2021, S1535-6108(21)00659-0
S1704 Emtricitabine (BW 1592) Emtricitabine (BW1592, FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
J Virol, 2021, JVI.01777-20
ACS Infect Dis, 2020, 10.1021/acsinfecdis.0c00536
JCI Insight, 2019, 4(12)
S5979New 2',3'-Dideoxyadenosine 2',3'-Dideoxyadenosine (ddA, ddAdo) is an anti-human immunodeficiency virus agent against human immunodeficiency virus (HIV) and human hepatitis B virus (HBV) replication.
S6729 Besifovir Besifovir is novel and potent acyclic nucleotide phosphonate used to treat hepatitis B virus (HBV) infection.
S8627 OSS_128167 OSS_128167 (SIRT6-IN-1) is a specific SIRT6 inhibitor with IC50 values of 89, 1578 and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-viral effect in HBV transcription and replication.
Front Cell Dev Biol, 2021, 9:625540
Front Cell Dev Biol, 2021, 9:648627
Mol Cell Biol, 2021, MCB.00047-21
S0796 JNJ-632 JNJ-632 is a potent hepatitis B virus (HBV) capsid assembly modulator (CAM) with mean EC50 of 121 nM in HepG2.2.15 cells.
S0038 AB-423 AB-423, a member of the sulfamoylbenzamide (SBA) class of hepatitis B virus (HBV) capsid inhibitors, shows potent inhibition of HBV replication with EC50 of 0.08 μM - 0.27 μM and EC90 of 0.33 μM - 1.32 μM in cells. Phase 1.
S0285 Bay 41-4109 racemate BAY 41-4109 racemate (BAY41-4109 Racemic) is a mixture of R-isomer of BAY 41-4109 and S-isomer of BAY 41-4109. BAY 41-4109 an antiviral compound that inhibits human hepatitis B virus (HBV) with IC50 of 53 nM.
Nat Commun, 2021, 12(1):2114
S1208 Doxorubicin (Adriamycin) HCl Doxorubicin (Adriamycin, NSC 123127, DOX, Hydroxydaunorubicin) HCl is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage, mitophagy and apoptosis in tumor cells. Doxorubicin reduces basal phosphorylation of AMPK. Doxorubicin is used in the concomitant treatment of HIV-infected patients but is found to be at high risk of HBV reactivation.
Oncol Rep, 2022, 47(1)18
Nat Genet, 2021, 10.1038/s41588-021-00893-0
Cancer Cell, 2021, S1535-6108(21)00659-0
S1704 Emtricitabine (BW 1592) Emtricitabine (BW1592, FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
J Virol, 2021, JVI.01777-20
ACS Infect Dis, 2020, 10.1021/acsinfecdis.0c00536
JCI Insight, 2019, 4(12)
S5979New 2',3'-Dideoxyadenosine 2',3'-Dideoxyadenosine (ddA, ddAdo) is an anti-human immunodeficiency virus agent against human immunodeficiency virus (HIV) and human hepatitis B virus (HBV) replication.
S6729 Besifovir Besifovir is novel and potent acyclic nucleotide phosphonate used to treat hepatitis B virus (HBV) infection.
S8627 OSS_128167 OSS_128167 (SIRT6-IN-1) is a specific SIRT6 inhibitor with IC50 values of 89, 1578 and 751 μM for SIRT6, SIRT1 and SIRT2, respectively. OSS_128167 has anti-viral effect in HBV transcription and replication.
Front Cell Dev Biol, 2021, 9:625540
Front Cell Dev Biol, 2021, 9:648627
Mol Cell Biol, 2021, MCB.00047-21
S0796 JNJ-632 JNJ-632 is a potent hepatitis B virus (HBV) capsid assembly modulator (CAM) with mean EC50 of 121 nM in HepG2.2.15 cells.
S5979New 2',3'-Dideoxyadenosine 2',3'-Dideoxyadenosine (ddA, ddAdo) is an anti-human immunodeficiency virus agent against human immunodeficiency virus (HIV) and human hepatitis B virus (HBV) replication.